Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Ruxolitinib XR vs IR
NCT06310304Phase 1Completed
- Sponsor
- Incyte
- Start
- Mar 2024
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ruxolitinib in myelofibrosis (MF), polycythemia vera (PV) and graft-versus-host disease (GVHD) (4 cohorts), sponsored by Incyte. Primary endpoint: Ruxolitinib Pharmacokinetics in Plasma. Started Mar 2024; status: completed.
02
Drugs
03
Conditions
myelofibrosis (MF)polycythemia vera (PV)graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT06310304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06310304.